Durable efficacy of frontline zanubrutinib in treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma in patients with del(17p): Extended median follow-up of SEQUOIA arm C

Superior progression-free survival with zanubrutinib plus rituximab vs bendamustine+rituximab in treatment-naïve mantle cell lymphoma: Primary analysis of a phase 3 study (MANGROVE)

Zanubrutinib plus venetoclax demonstrates durable efficacy across TP53 aberration and IGHV subgroups in treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma: 4-year follow-up of SEQUOIA arm D

Real-world impact of atrial fibrillation on cardiovascular outcomes in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma

Unanchored matching-adjusted indirect comparisons of control and treatment arms from MANGROVE and ECHO trials in first-line mantle cell lymphoma

Survival outcomes of first-line treatment with zanubrutinib in chronic lymphocytic leukemia from SEQUOIA: Comparison with a matched general population

Real-world overall survival of patients with chronic lymphocytic leukemia treated with frontline Bruton’s tyrosine kinase inhibitors: An analysis of a large US multi-payer claims database

Sonrotoclax plus zanubrutinib produces durable responses and achieves uMRD4 in 99% of patients with treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma: ~40-month follow-up from a phase 1/1b trial

Sustained benefit of zanubrutinib in relapsed/refractory marginal zone lymphoma: MAGNOLIA + LTE1

Long-term efficacy and safety of zanubrutinib in patients with relapsed/refractory mantle cell lymphoma: Up to 9 years of follow-up from BGB-3111-206 and AU-003

Zanubrutinib switch in patients with previously treated B-cell malignancies intolerant to previous Bruton tyrosine kinase inhibitors: Final results of a phase 2, open-label, single-arm study

Atrial fibrillation risk by age in patients with chronic lymphocytic leukemia treated with covalent Bruton tyrosine kinase inhibitors

Real-world treatment persistence and clinical outcomes among patients receiving first-line covalent Bruton tyrosine kinase inhibitors for chronic lymphocytic leukemia

MRD-guided treatment with sonrotoclax + obinutuzumab induces deep and durable remissions in treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma: Updated phase 1/1b study results

Sonrotoclax in combination with dexamethasone and daratumumab for t(11;14) relapsed/refractory multiple myeloma: Preliminary safety and efficacy results from the phase 1b/2 BGB-11417-105 study

Safety and tolerability of a simplified ramp-up schedule of sonrotoclax in combination with zanubrutinib in patients with treatment-naïve chronic lymphocytic leukemia: Initial results from a phase 1 global study

Tacabrutideg (BGB-16673), a Bruton tyrosine kinase degrader, in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma: Updated safety and efficacy data from the phase 1 CaDAnCe-101 study

Updated efficacy and safety of the Bruton tyrosine kinase degrader tacabrutideg (BGB-16673) in BTK inhibitor-naive patients with chronic lymphocytic leukemia/small lymphocytic lymphoma and other B-cell malignancies in the CaDAnCe-101 study

Tacabrutideg (BGB-16673), a Bruton tyrosine kinase degrader, in patients with relapsed/refractory Waldenström macroglobulinemia: Updated safety and efficacy data from the phase 1 CaDAnCe-101 study

Preclinical and clinical immune profiling of tacabrutideg (BGB-16673), a Bruton tyrosine kinase degrader, shows preserved T-cell function and maintenance of key non-B-cell immune compartments in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma

Biomarker analysis in patients treated with zanubrutinib and lenalidomide combination in relapsed/refractory diffuse large B-cell lymphoma

Effectiveness and safety of first-line zanubrutinib in chronic lymphocytic leukemia: The Spanish ReaLLCZa study

Symptoms associated with disease progression in chronic lymphocytic leukemia: Achieving expert clinician consensus through an international Delphi panel

Lifetime costs of CLL by first-line treatment selection: Continuous monotherapy zanubrutinib versus venetoclax-based regimens

Patient, caregiver, and provider perspectives on the burden of side effects in chronic lymphocytic leukemia

Development and validation of generative-model-derived synthetic cohorts for outcome prediction and comparative effectiveness research in chronic lymphocytic leukemia

Patient preferences for chronic lymphocytic leukemia treatment attributes in Canada: A discrete choice experiment

Real-world treatment patterns across the pre-Bruton’s tyrosine kinase inhibitor and BTKi era and time to next treatment in patients with mantle cell lymphoma in Japan

Treatment preferences and decision-making in first-line mantle cell lymphoma: Perspectives from patients, caregivers, and physicians

Comparison of progression-free survival and overall survival with zanubrutinib vs ibrutinib in treatment-naïve chronic lymphocytic leukemia: a number-needed-to-treat analysis

Comparative real-world analysis of intravenous immunoglobulin utilization in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma receiving venetoclax–obinutuzumab or zanubrutinib

Real-world comparative outcomes of zanubrutinib, acalabrutinib, and ibrutinib in chronic lymphocytic leukemia/small lymphocytic lymphoma: An AI-assisted systematic literature review and meta-analysis

Qualitative assessment of physician-documented drivers for switching cBTK inhibitors in CLL/SLL in real-world practice

Treatment landscape and survival outcomes among patients treated for mantle cell lymphoma in real-world practice

Estimating clinically meaningful change thresholds for a European Organisation for Research and Treatment of Cancer IL-409 proxy in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma: Results from the ALPINE trial

Sonrotoclax monotherapy demonstrates durable efficacy in patients with relapsed/refractory Waldenström macroglobulinemia: 31.5-month follow-up from a phase 1/1b study

Sonrotoclax monotherapy demonstrates durable clinical activity in relapsed/refractory marginal zone lymphoma: 30-month follow-up from an ongoing phase 1/1b study

Sonrotoclax plus azacitidine demonstrates broad antileukemic activity across ELN 2024 genetic risk groups in treatment-naïve acute myeloid leukemia unfit for intensive chemotherapy

Efficacy and safety of sonrotoclax in patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma: A 2-year follow-up from a multicenter, open-label, phase 2 study

Real-world treatment patterns, clinical, and economic outcomes following covalent Bruton tyrosine kinase inhibitor therapy in patients with mantle cell lymphoma in the United States

Understanding treatment preferences in relapsed/refractory mantle cell lymphoma: A cross-sectional survey of patients, caregivers, and physicians

Treatment patterns after prior double exposure to Bruton tyrosine kinase inhibitors and B-cell lymphoma 2 inhibitors in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma

BGB-16673 differentiates from other BTK degraders through potent intrinsic BTK inhibition that limits E3 ligase loss–driven resistance

Risk of hypertension in patients (pts) with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) receiving treatment with zanubrutinib or pirtobrutinib: a comparative real-world study